生物微球联合碘油经肝动脉栓塞化疗治疗原发性肝癌临床观察

doi:10.3969/j.issn.1672-5069.2015.02.007

摘要/Abstract

摘要： 目的观察生物微球联合碘油经肝动脉栓塞化疗（TACE）治疗不能手术切除的原发性肝癌患者的临床疗效。方法选择本院2010年1月至2012年12月40例行选择性肝动脉栓塞化疗时使用生物微球联合碘油栓塞化疗的原发性肝癌患者和42例行选择性肝动脉栓塞时使用碘油栓塞化疗的患者,每例行栓塞术4次以上,于首次术后1、3、6、12和24 m随访生存患者肝功能、甲胎蛋白、腹部增强CT等变化,比较治疗后病灶缩小程度,观察肿瘤部分缓解率及患者生存率。结果在首次术后3个月时,微球联合组肿瘤缓解率为（57.44%）,明显高于TACE组[（45.23%）,P<0.05],6个月时微球联合组AFP为（296.7±96.3）ng/ml,明显低于TACE组[（346.9±118.3）ng/ml,P<0.05],12个月时微球联合组肿瘤直径为（3.36±1.37）cm,明显低于TACE组[（4.98±1.87）cm,P<0.05],24个月时微球联合组生存率为（15.0%）,明显高于TACE组[（2.3%）,P<0.05]。结论生物微球联合碘油栓塞化疗治疗患者病灶缩小程度、AFP下降水平、肿瘤部分缓解率及患者生存率明显高于单纯碘油栓塞化疗组,生物微球联合碘油栓塞化疗治疗中晚期原发性肝癌疗效确切,临床疗效优于单纯栓塞化疗,且安全可行。

关键词: 原发性肝癌, 生物微球, 选择性肝动脉栓塞化疗, 疗效

Abstract: Objective To observe the clinical efficacy of selective transcatheter chemoembolization （TACE） with biologic microsphere and lipiodol in the treatment of patients with primary liver cancer （PLC）. Methods 82 patients with PLC in Daping hospital from January 2010 to December 2012 were included in this study and were divided into two groups. 42 patients received selective transcatheter chemoembolization with lipiodol,and 40 received selective transcatheter chemoembolization with both biologic microsphere and lipiodol. Each patient got chemoembolization at least four times. The follow-up assessment was conducted 1 month later as well as 3 months,6 months,1 year and 2 years later after the first treatment to follow-up the decreased volume and number of tumor masses,serum AFP levels,the remission rates and survival. Results The remission rate of 57.44% in patients treated with both biologic microsphere and lipiodol was obviously higher than that treated with lipiodol（TACE）（5.23%,P<0.05） 3 months after the first operation. The serum level of AFP in the combined group got much lower（296.7±96.3）ng/ml than in the TACE group[（346.9±118.3）ng/ml,P<0.05] 6 months later. We found that the diameters of tumors were much smaller（3.36±1.37） cm in the combined group than in the TACE group[（4.98±1.87）cm,P<0.05] 12 months later. And the survival rate in the combined group was much higher（15.0%） than that in the TACE group[（2.3%）,P<0.05] 24 months later. Conclusions Compared with patients treated with chemoembolization and lipiodol,patients receiving chemoembolization with both biologic microsphere and lipiodol get increased remission of tumor masses,as well as decreased serum AFP levels. Selective transcatheter chemoembolization with biologic microsphere and lipiodol is effective and safe in treatment of advanced liver cancer.

Key words: Hepatoma, Biologic microsphere, Lipiodol, Selective transcatheter chemoembolization, Efficacy

颜綦先, 肖潇, 崔红莉, 邵小娟, 张艳梅, 刘念, 杨洋, 陈东风, 王军. 生物微球联合碘油经肝动脉栓塞化疗治疗原发性肝癌临床观察[J]. 实用肝脏病杂志, 2015, 18(3): 245-248.

Yan Qixian, Xiao Xiao, Cui Hongli, et al.. Clinical observation of selective transcatheter chemoembolization with biologic microsphere and lipiodol in treatment of patients with primary liver cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(3): 245-248.

参考文献

[1] Kaibori M,Tanigawa N,Kariya S,et al. A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma. Dig Dis Sci,2012,57（5）:1404-1412.
[2] 杨秉辉,丛文铭,周晓军,等. 原发性肝癌规范化诊治的专家共识. 实用肝脏病杂志,2009,12（5）：321-328.
[3] 李发中,关文华,张卫东. PVA微粒联合碘化油栓塞化疗治疗肝细胞癌的中远期疗效评价. 中国医疗前沿,2013,8（12）:74-75.
[4] Minamiguchi H,Kawai N,Sato M,et al. Hepatoma feeding arteriogram created by CT during aortography using IVR 64-multidetector-row CT for catheterization in transcatheter arterial chemoembolization for hepatocellular carcinoma. Jpn J Radiol,2013,31（6）:428-436.
[5] 朱玉胜,吴林霖,颜志平. 国内肝细胞癌介入治疗的现状和进展. 中国介入放射学杂志,2009,15（35）：505-507.
[6] 李浩,祖茂衡.超液化碘油瘤内注射对肝癌细胞作用的实验研究. 中国介入影像与治疗学,2007,4（5）:353-357.
[7] Bae SI,Yeon JE,Lee JM,et al. A case of necrotizing pancreatitis subsequent to transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma. Clin Mol Hepatol,2012,18（3）:321-325.
[8] Yamamoto A,Imai S,Kobatake M,et al. Evaluation of trisacryl gelatin microsphere embolization with monochromatic X Rays:comparison with polyvinyl alcohol particles. J Vascinterv Radiol,2006,17（4）:1797-1802.
[9] Chung YH,Han G,Yoon JH,et al. Interim analysis of START: Study in Asia of the combination of TACE（transcatheter arterial chemoembolization） with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer,2013,132（10）:2448-2458.
[10] 褚建国,黄鹤,孙鹏,等. 功能性血流脾动脉栓塞术治疗脾功能亢进130例. 世界华人消化杂志,2010,18（24）:3704-3708.
[11] Weng LL,Xiang JF,Lin JB,et al. Asparagus polysaccharide and gum with hepatic artery embolization induces tumor growth and inhibits angiogenesis in an orthotopic hepatocellular carcinoma model.Asian Pac J Cancer Prev,2014,15（24）:10949-10955.
[12] Nishikawa H,Kita R,Kimura T,et al. Transcatheter arterial embolic therapies for hepatocellular. Anticancer Res,2014,34（12）:6877-6886.
[13] Minami Y,Yagyu Y,Murakami T,et al. Tracking navigation imaging of transcatheter arterial chemoembolization for hepatocellular carcinoma using three-dimensional cone-beam CT angiography. Liver Cancer,2014,3（1）:53-61.
[14] Abdel Samie A,Otto G,Theilmann L. Acute haemoperitoneum due to spontaneous tumour rupture as first manifestation of hepatocellular carcinoma. Z Gastroenterol,2007,45（7）:615-619.
[15] Fernández-Ruiz M1,Guerra-Vales JM,Llenas-García J,et al. Hemoperitoenum as presentation of hepatocellular carcinoma:experience in three cases with spontaneous tumoral rupture and review of the literature. An Med Interna,2008,25（2）:81-84.
[16] Miyoshi A,Kitahara K,Kohya N,et al. Outcomes of patients with spontaneous rupture of hepatocellular carcinoma. Hepatogastroenterology,2011,58（105）:99-102.
[18] Tarantino L,Sordelli I,Calise F,et al. Prognosis of patients with spontaneous rupture of hepatocellular carcinoma in cirrhosis. Updates Surg,2011,63（1）:25-30.
[19] Kirikoshi H,Saito S,Yoneda M,et a1. Outcomes and factors influencing survival in cirrhotic cases with spontaneous rupture of hepatocellular carcinoma: a multicenter study. BMC Gastroenterol,2009,91（3）：26-29.
[20] Bruls S,Joskin J,Chauveau R,et al. Ruptured hepatocellular carcinoma following transcatheter arterial chemoembolization.JBR BTR,2011,94（2）:68-70.